An antimineralocorticoid , MCRA ,  or an aldosterone antagonist , is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors . This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure . Spironolactone , the first member of the class, is also used in the management of hyperaldosteronism (including Conn's syndrome ) and female hirsutism (due to additional antiandrogen actions). Most antimineralocorticoids, including spironolactone, are steroidal spirolactones . Finerenone is a nonsteroidal antimineralocorticoid.
Bicalutamide has not been approved for use as monotherapy.
In one phase II clinical trial with bicalutamide used as a single agent, breast tenderness, breast swelling, and hot flashes were reported in %, %, and % of treated patients, respectively.
Another phase II clinical trial with bicalutamide used as a single agent reported breast pain, and gynecomastia in 76% and 60% of treated patients, respectively. This study also showed generalized pain in 30% of treated patients, hot flashes in 28%, pelvic pain in 26%, and libido decrease and impotence, both at 25%. [ Ref ]